News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

QTL Biosystems, LLC Introduces The First Real Time, Homogeneous Kinetic-Based Protein Kinase A (PKA) Assay To The Market

10/19/2005 5:09:45 PM

SANTA FE, N.M., Jan. 22 /PRNewswire/ -- QTL Biosystems, LLC, a provider of innovative solutions for bio-detection, drug discovery, and life science research, announced today the release of the QTL LIGHTSPEED(TM) PROTEIN KINASE A (PKA) Assay Kit. This assay utilizes a fluorescent polyelectrolyte-based super-quenching polymer that offers several advantages over conventional small molecule fluorescence. The QTL LIGHTSPEED(TM) platform provides single step, instantaneous, homogenous assays, and addresses a broad spectrum of drug targets in high-throughput screening.

The QTL LIGHTSPEED(TM) technology requires no radioactive material, antibodies, or wash steps. The platform is a simple mix and read format. "The Protein Kinase A assay relies on a novel improvement of LIGHTSPEED(TM) technology using metal ion-assisted superquenching. This provides real time kinetic and endpoint experimental results which is the first of its kind in the market for PKA assays," Stated Duncan McBranch, Ph.D., Co-founder and COO at QTL Biosystems.

Protein Kinase A is a cAMP dependent protein kinase which exerts its function as an effector of many cAMP messengers such as hormones and neurotransmitters. Its ubiquitous distribution and diversity of substrate recognition, makes PKA play a central role in the regulation of cellular processes. This includes the regulation of the immune response, mediation of depression, sensory nerve transmission, neuronal gene expression, motor learning, and lipolysis.

"The QTL LIGHTSPEED(TM) PROTEIN KINASE A assay is the first in a series of QTL assays which utilizes a completely new LIGHTSPEED(TM) metal ion platform. The new platform provides a general and versatile assay system for a host of Kinase and Phosphatase enzyme targets for the pharmaceutical and research community," stated David Whitten, Ph.D. Co-founder and CTO at QTL Biosystems.

ABOUT QTL Biosystems

QTL Biosystems, LLC is a supplier of amplification technologies for bioassays that accelerate and improve drug discovery, bio-detection, and other life sciences research. The Company's assay solutions facilitate the high-throughput and cost-effective identification and evaluation of drug candidates. The Company's advanced core technologies integrate its expertise in chemistry, molecular and cell biology and instrumentation. QTL Biosystems enables its customers to improve research productivity and effectiveness, which ultimately accelerates the complex process of discovering and developing new drugs.

Contact: Business Development QTL Biosystems, LLC 2778 Agua Fria Street, Bldg. C Santa Fe, NM 87507 (505) 424-1000, ext. 116 bd@qtlbio.com

This release was issued through eReleases(TM). For more information, visit

QTL Biosystems, LLC

CONTACT: Business Development, QTL Biosystems, LLC, +1-505-424-1000,ext. 116,

Read at

comments powered by Disqus